Novel downstream molecular targets of SIRT1 in melanoma: A quantitative proteomics approach

Oncotarget

Volumn 5, Issue 7, 2014, Pages 1987-1999

  Singh, Chandra K ^a   George, Jasmine ^a   Nihal, Minakshi ^a   Sabat, Grzegorz ^a   Kumar, Raj ^b   Ahmad, Nihal ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

BUB family proteins; Melanoma; Proteomics; shRNA; SIRT1; Tenovin 1

Indexed keywords

BUB1 RELATED PROTEIN; BUB3 PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; MESSENGER RNA; PROTEIN BUB1; PROTEIN HIS1H4A; PROTEIN INHIBITOR; PROTEIN MOCOS; PROTEIN MYO1B; PROTEIN PSAP; SIRTUIN 1; TENOVIN 1; UNCLASSIFIED DRUG; ACETANILIDE DERIVATIVE; BUB1 PROTEIN, HUMAN; BUB3 PROTEIN, HUMAN; CELL CYCLE PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MOCOS PROTEIN, HUMAN; MYO1B PROTEIN, HUMAN; MYOSIN I; PROTEIN SERINE THREONINE KINASE; PSAP PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN; SPHINGOLIPID ACTIVATOR PROTEIN; SULFURTRANSFERASE; TENOVIN-1; THIOUREA;

ARTICLE; CANCER CELL LINE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EXTRACTION; G361 CELL LINE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LENTIVIRINAE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENE ONTOLOGY; GENE SILENCING; GENETICS; METABOLISM; TUMOR CELL LINE;

ACETANILIDES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; GENE ONTOLOGY; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MELANOMA; MYOSIN TYPE I; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; RNA, MESSENGER; SAPOSINS; SIRTUIN 1; SULFURTRANSFERASES; THIOUREA;

EID: 84898950030     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1898     Document Type: Article

References (46)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-241.
3. Wilking MJ, Singh CK, Nihal M, Zhong W and Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys. 2014; (Submitted).
4. Singh CK, Wilking MJ, Nihal M, Wood GS and Ahmad N. Tenovin-1, a small-molecule inhibitor of SIRT1, imparts anti-proliferative response in human melanoma cells via p53 activation. J Invest Dermatol. 2012; 132:S123-S134 doi:101038/jid201290.
5. North BJ and Verdin E. Sirtuins: Sir2-related NADdependent protein deacetylases. Genome Biol. 2004; 5(5):224.
6. Sebastian C, Satterstrom FK, Haigis MC and Mostoslavsky R. From sirtuin biology to human diseases: an update. J Biol Chem. 2012; 287(51):42444-42452.
7. Carafa V, Nebbioso A and Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol. 2012; 3:4.
8. Imai S and Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci. 2010; 31(5):212-220.
9. Bruzzone S, Parenti MD, Grozio A, Ballestrero A, Bauer I, Del Rio A and Nencioni A. Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des. 2013; 19(4):614-623.
10. Roth M and Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 2013; 1-12. doi:10.1038/onc.2013.120.
11. Yuan H, Su L and Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. OncoTargets Ther. 2013; 6:1399-1416.
12. Jung-Hynes B, Nihal M, Zhong W and Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem. 2009; 284(6):3823-3832.
13. Nihal M, Ahmad N and Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma and its inhibition induces growth arrest and apoptosis. Cell cycle. 2013; 13(4):632-40.
14. Kriegl L, Vieth M, Kirchner T and Menssen A. Upregulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget. 2012; 3(10):1182-1193.
15. Stenzinger A, Endris V, Klauschen F, Sinn B, Lorenz K, Warth A, Goeppert B, Ehemann V, Muckenhuber A, Kamphues C, Bahra M, Neuhaus P and Weichert W. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC cancer. 2013; 13:450.
16. Hida Y, Kubo Y, Murao K and Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007; 299(2):103-106.
17. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Yu TK, Kim KM, Park HS, Lee JH, Moon WS, Lee H, Chung MJ and Jang KY. Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PloS one. 2013; 8(9):e74738.
18. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS and Jang KY. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Human pathol. 2011; 42(2):204-213.
19. Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW and Sylvester KG. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PloS one. 2012; 7(9):e45119.
20. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci. 2009; 5(2):147-152.
21. Wasinger VC, Zeng M and Yau Y. Current status and advances in quantitative proteomic mass spectrometry. Int J Proteomics. 2013; 2013:180605.
22. Liang S, Xu Z, Xu X, Zhao X, Huang C and Wei Y. Quantitative proteomics for cancer biomarker discovery. Comb Chem High T Scr. 2012; 15(3):221-231.
23. Knight JR and Milner J. SIRT1, metabolism and cancer. Curr Opin Oncol. 2012; 24(1):68-75.
24. Kirkin V and Dikic I. Ubiquitin networks in cancer. Curr Opin Genet Dev. 2011; 21(1):21-28.
25. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008; 13(5):454-463.
26. Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE and Mueller W. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer--association with tumour cell proliferation. J Pathol. 2003; 200(1):16-22.
27. Pinto M, Vieira J, Ribeiro FR, Soares MJ, Henrique R, Oliveira J, Jeronimo C and Teixeira MR. Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol. 2008; 30(5):389-395.
28. Maciejczyk A, Szelachowska J, Czapiga B, Matkowski R, Halon A, Gyorffy B and Surowiak P. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem. 2013; 61(5):330-339.
29. Bolanos-Garcia VM and Blundell TL. BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends Biochem Sci. 2011; 36(3):141-150.
30. Elowe S. Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint. Mol Cell Biol. 2011; 31(15):3085-3093.
31. Revollo JR and Li X. The ways and means that fine tune Sirt1 activity. Trends Biochem Sci. 2013; 38(3):160-167.
32. Song NY and Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci. 2012; 1271:10-19.
33. Amaral JD, Xavier JM, Steer CJ and Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010; 9(45):145-152.
34. Benjamin CL, Melnikova VO and Ananthaswamy HN. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008; 624:265-282.
35. Schmidt M and Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat. 2007; 10(4-5):162-181.
36. Logarinho E and Bousbaa H. Kinetochore-microtubule interactions "in check" by Bub1, Bub3 and BubR1: The dual task of attaching and signalling. Cell cycle. 2008; 7(12):1763-1768.
37. Kitagawa K and Niikura Y. Caspase-independent mitotic death (CIMD). Cell cycle. 2008; 7(8):1001-1005.
38. Morales AG, Pezuk JA, Brassesco MS, de Oliveira JC, de Paula Queiroz RG, Machado HR, Carlotti CG, Jr., Neder L, de Oliveira HF, Scrideli CA and Tone LG. BUB1 and BUBR1 inhibition decreases proliferation and colony formation, and enhances radiation sensitivity in pediatric glioblastoma cells. Childs Nerv Syst. 2013; 29(12):2241- 2248.
39. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K and Gabrielson E. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006; 12(2):405-410.
40. Hu M, Liu Q, Song P, Zhan X, Luo M, Liu C, Yang D, Cai Y, Zhang F, Jiang F, Zhang Y, Tang M, Zuo G, Zhou L, Luo J, Shi Q, et al. Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the antimicrotubule drug resistance of esophageal squamous cell carcinoma cells. Oncol Rep. 2013; 29(1):185-192.
41. Keller A, Nesvizhskii AI, Kolker E and Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002; 74(20):5383-5392.
42. Nesvizhskii AI, Keller A, Kolker E and Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003; 75(17):4646-4658.
43. Wang X, Spandidos A, Wang H and Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 2012; 40(Database issue):D1144-1149.
44. Maresca G, Natoli M, Nardella M, Arisi I, Trisciuoglio D, Desideri M, Brandi R, D'Aguanno S, Nicotra MR, D'Onofrio M, Urbani A, Natali PG, Del Bufalo D, Felsani A and D'Agnano I. LMNA knock-down affects differentiation and progression of human neuroblastoma cells. PloS one. 2012; 7(9):e45513.
45. Assidi M, Montag M, Van der Ven K and Sirard MA. Biomarkers of human oocyte developmental competence expressed in cumulus cells before ICSI: a preliminary study. J Assist Reprod Genet. 2011; 28(2):173-188.
46. Schmit TL, Nihal M, Ndiaye M, Setaluri V, Spiegelman VS and Ahmad N. Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res. 2012; 72(15):3864-3872.